Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methicillin Sodium

FDA-approved product (injectable, injection), marketed as Staphcillin.

Registered studies
50+
Lab records
29
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Methicillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF03

Repurposing investigation

Methicillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA10.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae10.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 8 of 26 lab records
  • E. coli: measured active in 0 of 2 lab records
  • K. pneumoniae: measured active in 0 of 1 lab record
Open Methicillin Sodium in ChEMBL Registered studies below
Show the 29 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methicillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia

    NCT00326287 · start 2006-06

    Registered record
    Registry ID
    NCT00326287
    Conditions
    Pneumonia
    Interventions
    Ceftobiprole medocaril; Ceftriaxone with or without Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-06
    Completion
    2007-07
    Enrolment
    638

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionCeftobiprole medocaril; Ceftriaxone with or without Linezolid
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

    NCT00107952 · start 2005-02

    Registered record
    Registry ID
    NCT00107952
    Conditions
    Bacterial Pneumonia
    Interventions
    Telavancin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2007-07
    Enrolment
    761

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Pneumonia
    InterventionTelavancin; Vancomycin
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

    NCT00124020 · start 2005-01

    Registered record
    Registry ID
    NCT00124020
    Conditions
    Bacterial Pneumonia
    Interventions
    Telavancin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-01
    Completion
    2007-05
    Enrolment
    771

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Pneumonia
    InterventionTelavancin; Vancomycin
    PhasePhase 3
    Registry statusCompleted

  • An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

    NCT00289588 · start 2005-01

    Registered record
    Registry ID
    NCT00289588
    Conditions
    Community-Acquired MRSA Infections; Abscesses; Cellulitis; Folliculitis
    Interventions
    Mupirocin (drug)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-01
    Completion
    2005-12
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-Acquired MRSA Infections; Abscesses; Cellulitis; Folliculitis
    InterventionMupirocin (drug)
    PhaseNot applicable
    Registry statusCompleted

  • Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia

    NCT07186894 · start 2000-01-01

    Registered record
    Registry ID
    NCT07186894
    Conditions
    Bacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    Interventions
    Antistaphylococcal penicillins; Cefazolin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2000-01-01
    Completion
    2026-09-01
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    InterventionAntistaphylococcal penicillins; Cefazolin
    PhaseNot recorded
    Registry statusActive not recruiting